OR WAIT null SECS
© 2023 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
June 28, 2016
Norgine (Amsterdam, The Netherlands) has completed the divestment of its MENA (Middle East and Africa) operations and rights for a number of its products in MENA to Acino (Aesch, Switzerland).
Kalle Känd, CEO of Acino said: “The products [MOVICOL, MOVIPREP, KLEAN-PREP and NORMACOL] are complementary to our existing portfolio in these markets and will considerably strengthen our offer in one of our core therapeutic areas – gastroenterology.”
The transaction includes the transfer of Norgine’s employees and entities in Egypt and employees in Tunisia. Norgine will continue to manufacture its own products for Acino.
Financial terms were not disclosed.